参考文献/References:
［1］Lidegaard ，Nielsen LH，Skovlund CW，et al Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9［J］. BMJ，2011，343(16)：d6423.
［2］Peragallo Urrutia R，Coeytaux RR，McBroom AJ，et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis ［J］. Obstet Gynecol，2013，122（2 Pt 1）：380-389.
［3］Centers for Disease Control, Prevention. U［EB/OL］［2018-05-09］. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5904a1. htm.
［4］Centers for Disease Control, Prevention. U.S.selected practice recommendations for contraceptive use,2013:adapted from the World Health Organization selected practice recommendations for contraceptive use,2nd edition ［J］. MMWR. Recommendations and Reports： Morbidity and Mortality Weekly Report. Recommendations and Reports / Centers for Disease Control, 2013, 62(RR/5): 1-60.
［5］Phvwp monthly report on safety concerns，guidelines and general matters.［EB/OL］.（2009-10-18）.［2014-05-10］.http：//www.ema.europa.eu/docs/en_GB/document_library/Report/2009/10/WC500006181.pdf.
［6］CEA-SORIANO L, GARCIA RODRIGUEZ L A, MACHLITT A . Use of prescription contraceptive methods in the UK general population: a primary care study ［J］. BJOG-An International Journal of Obstetrics and Gynaecology, 2014, 121(1): 53-61.
［7］World Health Organization. Medical eligibility criteria for contraceptive use ［Z］. 5th ed, 2015.
［8］Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016：Prevention Morbidity and Mortality Weekly Report ［J］. MMWR Recomm Rep，2016, 65(3):22-27.2016, 65(3):56-68.
［9］Centers for Disease Control, Prevention. U.S.selected practice recommendations for contraceptive use,2016:prevention morbidity and mortality weekly report ［J］. MMWR. Recommendations and Reports： Morbidity and Mortality Weekly Report. Recommendations and Reports / Centers for Disease Control, 2016, 65(4): 22-27.
［10］BUSHNELL C, MCCULLOUGH L D, AWAD I A, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association ［J］. Stroke; a Journal of Cerebral Circulation, 2014, 45(5): 1545-1588.
［11］BARTON M. Cholesterol and atherosclerosis: modulation by oestrogen ［J］. Current Opinion in Lipidology, 2013, 24(3): 214-220.
［12］MICHIHISA UMETANI P G, PHILIP W. Shaul.the cholesterol metabolite 27-Hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha［J］. Cell Metabolism, 2014, 20(1): 172–182.
［13］LIU Hui, YAO Jie, WANG Wei-jing, et al. Association between duration of oral contraceptive use and risk of hypertension: A meta-analysis［J］. Journal of Clinical Hypertension, 2017, 19(10): 1032-1041.
［14］WANG Fu-sheng, FAN Jian-gao, ZHANG Zheng, et al. The global burden of liver disease: the major impact of China ［J］. Hepatology (Baltimore, Md.), 2014, 60(6): 2099-2108.
［15］SCHWEITZER A, HORN J, MIKOLAJCZYK R T, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 ［J］. Lancet, 2015, 386(13): 1546-1555.
［16］Jue Liu, Shikun Zhang, Min Liu, et al. Maternal pre-pregnancy infection with hepatitis B virus and the risk of preterm birth: a population-based cohort study ［J］. Lancet Glob Health, 2017,5: e624–632.
［17］L S. Mrch, C W Skovlund, P C. Hannaford, et al.Contemporary Hormonal Contraception and the Risk of Breast Cancer ［J］. N Engl J Med, 2017, 377(23):2228.
［18］Committee on Gynecologic Practice. American college of obstetricians and gynecologists.committee opinion no 544:over-the-counter access to oral contraceptives［J］. Obstetrics and Gynecology, 2012, 120(6): 1527-1531.
［19］European Medicines Agency. Benefits of Diane 35 and its generics outweigh risks in certain patient groups ［EB/OL］. http://website www.ema.europa.eu/ EMA/318380/2013.
［20］AGENCY E M. European medicines agency starts safety review of diane 35 and its generics［EB/OL］［2018-05-09］. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/02/WC500138604.pdf.
［21］AGENCY E M. Benefits of combined hormonal contraceptives(CHCs)continue to outweigh risks［EB/OL］. (2014-06-02)［2018-05-09］. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Combined_hormonal_contraceptives/European_Commission_final_decision/WC500160277.pdf.
［22］LIDEGAARD , LKKEGAARD E, JENSEN A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception ［J］. New England Journal of Medicine, 2012, 366(24): 2257-2266.
［23］Peragallo UR, Coeytaux RR, McBroom AJ, et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis ［J］. Obstet Gynecol， 2013，22(2 Pt 1):380-389.
［24］IVERSEN L, SIVASUBRAMANIAM S, AMANDA J, et al. Lifetime cancer risk and combined oral contraceptives:the Royal College of General Practitioners'Oral Contraception Study［J］. American Journal of Obstetrics and Gynecology, 2017, 216(580): e1-e9.
［25］MICHELS K A, PFEIFFER R M, BRINTON L A. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers ［J］. JAMA ONCOLOGY, 2018, 4(4): 516-521.
［26］复方口服避孕药临床应用中国专家共识专家组(2015).复方口服避孕药临床应用中国专家共识 ［J］. 中华妇产科杂志，2015，50(2)：81-91.